KA - Rasio utang marang kapitalisasi buku Kineta, Inc.

The trajectory of Kineta, Inc. (KA) financial leverage underscores the business's autonomy from macroeconomic fluctuations, rendering the asset defensive. The value of 0.00 reflects the balance of debt metrics. Kineta, Inc. (KA) relies on its unique drug KVA12.1, which possesses significant pricing power. However, the company operates amidst fierce competition for investment and the risk of more effective therapeutic solutions emerging.

The metric is calculated as the ratio of total borrowed funds to net asset value, determining the business's degree of dependence on external financing relative to its own equity. For Kineta, Inc. (KA), this balance is critical when developing costly cancer immunotherapy research. A high debt load could limit investments in the scientific foundation. The historical trend of the debt-to-equity ratio reflects the current financial stability of the company.